{"id":"placebo-valdecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiovascular events (myocardial infarction, stroke)"},{"rate":null,"effect":"Gastrointestinal ulceration"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL865","moleculeType":"Small molecule","molecularWeight":"314.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valdecoxib is a selective COX-2 inhibitor that preferentially blocks the inducible cyclooxygenase-2 enzyme while sparing COX-1, thereby reducing inflammatory prostaglandins while theoretically preserving gastroprotective prostaglandins. This selective inhibition provides anti-inflammatory and analgesic effects with potentially fewer gastrointestinal side effects compared to non-selective NSAIDs.","oneSentence":"Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:59.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain"},{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"}]},"trialDetails":[{"nctId":"NCT03915561","phase":"PHASE2","title":"Effect of Intravenous Dynastat on Postoperative Sore Throat","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2019-03-01","conditions":"Sore Throat, Postoperative Complications","enrollment":140},{"nctId":"NCT00650624","phase":"PHASE2","title":"A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-06","conditions":"Osteoarthritis, Knee","enrollment":416},{"nctId":"NCT00653354","phase":"PHASE3","title":"Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-12","conditions":"Pain, Post-surgical","enrollment":360},{"nctId":"NCT00092339","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08-01","conditions":"Postoperative Pain","enrollment":125},{"nctId":"NCT00092300","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Postoperative Pain","enrollment":450},{"nctId":"NCT00021996","phase":"NA","title":"Valdecoxib in Treating Chronic Pain in Cancer Patients","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-01","conditions":"Pain, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00651300","phase":"PHASE3","title":"A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-04","conditions":"Pain","enrollment":91},{"nctId":"NCT00636064","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Pain","enrollment":1671},{"nctId":"NCT00650455","phase":"PHASE4","title":"Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Arthritis, Rheumatoid","enrollment":489},{"nctId":"NCT00650039","phase":"PHASE3","title":"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-03","conditions":"Pain","enrollment":488},{"nctId":"NCT00683137","phase":"PHASE3","title":"Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-10","conditions":"Pain, Hallux Valgus","enrollment":450},{"nctId":"NCT00647829","phase":"PHASE3","title":"A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Pharyngitis","enrollment":197},{"nctId":"NCT00661635","phase":"PHASE3","title":"A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Laparoscopic Cholecystectomy, Pain","enrollment":490}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo/Valdecoxib","genericName":"Placebo/Valdecoxib","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Acute pain, Rheumatoid arthritis, Osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}